These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31124724)

  • 1. Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Salvo EM; Samjoo IA; Tran D; Cameron C
    Expert Opin Pharmacother; 2019 Aug; 20(12):1527-1528. PubMed ID: 31124724
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Lin H; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Aug; 20(12):1529-1530. PubMed ID: 31124741
    [No Abstract]   [Full Text] [Related]  

  • 3. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Labeyrie C; Merkel M; Sethi S; Popadic L; Yang H; Sweetser MT; Lin H; Adams D
    Eur J Neurol; 2024 Sep; 31(9):e16384. PubMed ID: 38988097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
    Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis.
    Lin H; Merkel M; Hale C; Marantz JL
    Neurodegener Dis Manag; 2020 Oct; 10(5):289-300. PubMed ID: 32519928
    [No Abstract]   [Full Text] [Related]  

  • 8. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
    J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patisiran in hereditary transthyretin-mediated amyloidosis.
    Luigetti M; Servidei S
    Lancet Neurol; 2021 Jan; 20(1):21-23. PubMed ID: 33212064
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
    Samjoo IA; Salvo EM; Tran D; Amass L; Stewart M; Cameron C
    Curr Med Res Opin; 2020 May; 36(5):799-808. PubMed ID: 32011182
    [No Abstract]   [Full Text] [Related]  

  • 12. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 14. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
    Yang J
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
    JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy.
    Müschen LH; Körner G; Gingele S; Hänselmann A; Bavendiek U; Skripuletz T
    Muscle Nerve; 2021 Sep; 64(3):E11-E13. PubMed ID: 34075597
    [No Abstract]   [Full Text] [Related]  

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.